.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
Daiichi Sankyo
Julphar
Accenture
AstraZeneca
McKinsey
Chubb
Fish and Richardson
Express Scripts

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,870,827

« Back to Dashboard

Which drugs does patent 8,870,827 protect, and when does it expire?


Patent 8,870,827 protects EPIPEN and EPIPEN JR. and is included in one NDA. There have been zero Paragraph IV challenges on Epipen and Epipen Jr.

This patent has thirty-three patent family members in seventeen countries.

Summary for Patent: 8,870,827

Title:Automatic injector
Abstract: An automatic injector dispenses a predetermined dose of medicament without a user having to manually force the needle into an injection site. The automatic injector includes a needle cover having a locked retracted position with respect to the injector housing prior to a medicament dispensing operation. The needle cover is operative to engage an injection site prior to a medicament dispensing operation.
Inventor(s): Young; Matthew Egerton (Over Cambs, GB), Raven; Sophie Rebecca (Swavesey Cambs, GB), Hurlstone; Christopher John (Newport Saffron Walden, GB), Rochford; Craig Malcolm (Monxton Andover Hants, GB), Mathews; Colin James (Godmanchester Huntingdon, GB), Hill; Robert L. (Abingdon, MD), Wilmot; John Glyndwr (Mount Airy, MD)
Assignee: Meridian Medical Technologies, Inc. (Columbia, MD)
Application Number:12/857,641
Patent Claim Types:
see list of patent claims
Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mylan Speciality LpEPIPENepinephrineINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS019430-001Dec 22, 1987BXRXYesYes► Subscribe► SubscribeY► Subscribe
Mylan Speciality LpEPIPEN JR.epinephrineINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS019430-002Dec 22, 1987BXRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,870,827

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,449,012Automatic injector► Subscribe
9,586,010Automatic injector with needle cover► Subscribe
8,048,035Automatic injector with needle cover► Subscribe
7,794,432Automatic injector with kickback attenuation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,870,827

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2683253► Subscribe
China101166551► Subscribe
Cyprus1115201► Subscribe
Cyprus1117076► Subscribe
Cyprus1117383► Subscribe
Denmark1786491► Subscribe
European Patent Office1786491► Subscribe
European Patent Office2179759► Subscribe
European Patent Office2204201► Subscribe
European Patent Office2311510► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
McKinsey
Federal Trade Commission
Dow
QuintilesIMS
Merck
Boehringer Ingelheim
Covington
Daiichi Sankyo
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot